Headlines about Baxter International (NYSE:BAX) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.4620482558735 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Baxter International (BAX) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Noteworthy Movers: CONSOL Energy Inc. (NYSE:CNX), Baxter International Inc. (NYSE:BAX) – The Oracle Examiner (oracleexaminer.com)
- Notable Active Runners: Baxter International Inc., (NYSE: BAX … – Global Export Lines (press release) (globalexportlines.com)
- Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK – Nasdaq (nasdaq.com)
- Early Moves to Watch: Baxter International Inc (NYSE: BAX) – Alpha Beta Stock (alphabetastock.com)
A number of research firms have weighed in on BAX. Barclays upped their target price on Baxter International from $73.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. BMO Capital Markets upped their target price on Baxter International from $74.00 to $77.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Royal Bank of Canada restated a “hold” rating and set a $72.00 target price on shares of Baxter International in a report on Friday, February 2nd. Zacks Investment Research upgraded Baxter International from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price for the company in a report on Wednesday, January 3rd. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $71.27.
Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, beating the consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.77 billion. During the same quarter in the prior year, the business posted $0.57 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. research analysts forecast that Baxter International will post 2.78 earnings per share for the current fiscal year.
Baxter International announced that its Board of Directors has approved a stock repurchase plan on Tuesday, February 20th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 2nd. Stockholders of record on Friday, March 2nd will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, March 1st. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. Baxter International’s dividend payout ratio is presently 49.61%.
In related news, Director Carole J. Shapazian sold 4,990 shares of the company’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $66.05, for a total value of $329,589.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.